期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 363, 期 16, 页码 1532-1543出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1008433
关键词
-
资金
- British Columbia (BC) Cancer Foundation
- Vancouver General Hospital (VGH)-University of British Columbia Hospital Foundation
- Canadian Institutes of Health Research (CIHR)
- Genome Canada
- OvCaRe
- Michael Smith Foundation for Health Research (MSFHR)
- CIHR [STP-53912]
- Canadian Breast Cancer Foundation
- Canada Research Chair in Molecular Oncology
- Sanofi-Aventis, Canada
- Ovarian Cancer Canada
- U.S. Army Medical Research and Materiel Command [DAMD17-O1-1-0729]
- Cancer Council Tasmania
- Cancer Foundation of Western Australia
- National Health and Medical Research Council of Australia
- National Cancer Institute, National Institutes of Health [RO1CA103937, RO1CA129080]
BACKGROUND Ovarian clear-cell and endometrioid carcinomas may arise from endometriosis, but the molecular events involved in this transformation have not been described. METHODS We sequenced the whole transcriptomes of 18 ovarian clear-cell carcinomas and 1 ovarian clear-cell carcinoma cell line and found somatic mutations in ARID1A (the AT-rich interactive domain 1A [SWI-like] gene) in 6 of the samples. ARID1A encodes BAF250a, a key component of the SWI-SNF chromatin remodeling complex. We sequenced ARID1A in an additional 210 ovarian carcinomas and a second ovarian clear-cell carcinoma cell line and measured BAF250a expression by means of immunohistochemical analysis in an additional 455 ovarian carcinomas. RESULTS ARID1A mutations were seen in 55 of 119 ovarian clear-cell carcinomas (46%), 10 of 33 endometrioid carcinomas (30%), and none of the 76 high-grade serous ovarian carcinomas. Seventeen carcinomas had two somatic mutations each. Loss of the BAF250a protein correlated strongly with the ovarian clear-cell carcinoma and endometrioid carcinoma subtypes and the presence of ARID1A mutations. In two patients, ARID1A mutations and loss of BAF250a expression were evident in the tumor and contiguous atypical endometriosis but not in distant endometriotic lesions. CONCLUSIONS These data implicate ARID1A as a tumor-suppressor gene frequently disrupted in ovarian clear-cell and endometrioid carcinomas. Since ARID1A mutation and loss of BAF250a can be seen in the preneoplastic lesions, we speculate that this is an early event in the transformation of endometriosis into cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据